LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

LLY

1,017.78

+0.18%↑

JNJ

246.5

+0.85%↑

ABBV

224.16

-1.4%↓

NVS

163.35

-1.12%↓

MRK

122.26

+1.34%↑

Search

Simulations Plus Inc

Abierto

SectorSanidad

12 -1.4

Resumen

Variación precio

24h

Actual

Mínimo

11.59

Máximo

12.25

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

110.024

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+55.99% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.26%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-120M

248M

Apertura anterior

13.4

Cierre anterior

12

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

165 / 351 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 feb 2026, 22:31 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 feb 2026, 22:18 UTC

Ganancias

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 feb 2026, 22:11 UTC

Ganancias

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 feb 2026, 21:52 UTC

Ganancias

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 feb 2026, 23:56 UTC

Charlas de Mercado

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 feb 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 feb 2026, 23:34 UTC

Charlas de Mercado
Ganancias

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 feb 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 feb 2026, 23:32 UTC

Charlas de Mercado

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 feb 2026, 22:45 UTC

Ganancias

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 feb 2026, 22:44 UTC

Charlas de Mercado

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q EPS $1.18 >NTR.T

18 feb 2026, 22:37 UTC

Ganancias

Nutrien 4Q Sales $5.34B >NTR.T

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q EPS $1.07 >PAAS

18 feb 2026, 22:35 UTC

Ganancias

Pan American Silver 4Q Rev $1.18B >PAAS

18 feb 2026, 22:30 UTC

Ganancias

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 feb 2026, 22:29 UTC

Ganancias

Kinross Gold 4Q EPS 75c >K.T

18 feb 2026, 22:22 UTC

Ganancias

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 feb 2026, 22:22 UTC

Charlas de Mercado

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 feb 2026, 22:16 UTC

Ganancias

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 feb 2026, 22:05 UTC

Ganancias

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 feb 2026, 22:03 UTC

Ganancias

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q Sales $929M >KALU

18 feb 2026, 22:02 UTC

Ganancias

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Adj EPS 67c >KGC

18 feb 2026, 22:00 UTC

Ganancias

Kinross Gold 4Q Sales $2.02B >KGC

18 feb 2026, 21:56 UTC

Ganancias

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 feb 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

55.99% repunte

Estimación a 12 Meses

Media 19 USD  55.99%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

165 / 351 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat